Compass Therapeutics, Inc. (CMPX)
(Real Time Quote from BATS)
$1.01 USD
+0.11 (12.22%)
Updated Aug 8, 2024 09:44 AM ET
3-Hold of 5 3
B Value F Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CMPX 1.01 +0.11(12.22%)
Will CMPX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CMPX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CMPX
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's Why
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know
CMPX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compass Therapeutics, Inc. (CMPX) Loses -28.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for CMPX
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
Buy Rating Affirmed on Compass Therapeutics as Clinical Trials of CTX-009 Show Promise in Biliary Tract Cancer Treatment
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
Compass Therapeutics completes patient enrollment in COMPANION-002
Compass Therapeutics: Pointing Right At Some Tough Cancers